VRP Verona Pharma Plc

 
TIDMVRP TIDMVRP 
 
 
   LONDON, March 08, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, announces that, on March 7, 2018, Dr. 
Jan-Anders Karlsson, Chief Executive Officer of the Company, purchased 
3,250 ordinary shares of 5 pence each in the Company (the "Ordinary 
Shares") at a price of 148.64 pence per Ordinary Share.  Following the 
acquisition, Dr. Karlsson will have an interest in the Company of 92,400 
Ordinary Shares, representing 0.09% of the Company's issued share 
capital. 
 
   The notification set out below is provided in accordance with the 
requirements of the EU Market Abuse Regulation. 
 
 
 
 
1     Details of the person discharging managerial responsibilities/person 
       closely associated 
a)    Name                                                         Jan-Anders Karlsson 
2     Reason for the notification 
                                                                   Chief Executive Officer 
  a)    Position/status 
b)    Initial notification/Amendment                               Initial notification 
3     Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
a)    Name                                                         Verona Pharma plc 
b)    LEI                                                          213800EVI6O6J3TIAL06 
4     Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place 
       where transactions have been conducted 
a)    Description of the financial instrument, type of instrument  Ordinary Shares of 5 pence each 
       Identification code                                          GB00BYW2KH80 
b)    Nature of the transaction                                    Jan-Anders Karlsson purchased 3,250 
                                                                   Ordinary Shares 
c)    Price(s) and volume(s)                                           Price(s)             Volume(s) 
                                                                   148.64 pence per      3,250 Ordinary 
                                                                    Ordinary Share            Shares 
d)    Aggregated information                                       N/A 
       - Aggregated volume 
       - Price 
e)    Date of the transaction                                      7 March 2018 
f)    Place of the transaction                                     London Stock Exchange, AIM 
 
 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                  Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive Officer       info@veronapharma.com 
 
Stifel Nicolaus Europe Limited (Nominated Adviser  Tel: +44 (0) 20 7710 7600 
 and UK Broker)                                     SNELVeronaPharma@stifel.com 
Stewart Wallace / Jonathan Senior / Ben Maddison 
 
 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Verona Pharma plc via Globenewswire 
 
 
  http://www.veronapharma.com/ 
 

(END) Dow Jones Newswires

March 08, 2018 08:38 ET (13:38 GMT)

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024

Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024